| HOME >> BIOLOGY >> TECHNOLOGY |
Partnership integral piece of consortium recently awarded five-year, $6.7 million Susan G. Komen for the Cure Promise Grant
WASHINGTON, April 29 /PRNewswire/ -- Thomas Jefferson University's Kimmel Cancer Center has partnered with DecisionQ, a leader in predictive analytics and machine learning to uncover life-saving answers hidden in the center's proprietary and extensive cancer registries. DecisionQ will leverage its expertise in developing predictive algorithms to identify how patients will respond to different therapeutic options for breast and colon cancers.
The team is part of a consortium that was recently awarded a Susan G. Komen for the Cure Promise Grant of nearly $6.7 million for five years of continued breast cancer research. Promise grants support multi-disciplinary research with the greatest potential to significantly reduce breast cancer incidence and/or mortality within the next decade.
"Identification of therapy-relevant biomarkers is a crucial part of breast cancer research, as there are many different biomarkers that could predict treatment response and outcome, and serve as targets for treatment," said Hallgeir Rui, M.D., Ph.D., professor of Cancer Biology at
Leading experts in the fields of decision analysis, statistics and machine learning have developed the technology and approach that DecisionQ applies in creating MMIA's (multi marker interpretive assays), greatly enhancing the quality of human judgment in an interactive, real-time environment at a low
'/>"/>
| SOURCE DecisionQ Corporation Copyright©2009 PR Newswire. All rights reserved |